Background: To alert for the diagnosis of the 22q11.2 deletion syndrome (22q11.2DS) in patients with congenital heart disease (CHD).
Introduction
The 22q11.2 deletion syndrome (22q11.2DS) is considered the most frequent chromosomal microdeletion syndrome in humans, with an incidence of 1:4,000-5,000 live births 1, 2 . This syndrome is currently recognized as occurring with a higher frequency than previously estimated, although precise information about its incidence in our country are unknown.
Microdeletions in the 22q11.2 region can occur in various syndromes such as the DiGeorge (DGS), velocardiofacial and the conotruncal anomaly face syndromes. These diseases represent different phenotypes of the same chromosomal abnormality, which are currently grouped and titled 22q11.2DS 1, 3 . This microdeletion is not detected on G-banding karyotyping, a routine cytogenetic exam. The molecular diagnosis of the syndrome is rather established by other techniques such as fluorescence in situ hybridization (FISH) and/or quantitative genomic analysis by multiplex ligation-dependent probe amplification (MLPA) 4, 5 .
Congenital heart diseases (CHDs) are one of the most frequent malformations, with an incidence that ranges from 8 to 10 per 1,000 live births, representing an important cause of morbimortality in the first year of life 6 . The etiology of cardiopathies associated with other types of congenital malformations can be monogenic, as in Holt-Oram, Marfan, Fanconi and Noonan syndromes, or chromosomal, as in Down, 22q1.2DS, 18 trisomy (Edwards) and 13 trisomy (Patau) syndromes 7 . CHDs with conotruncal defects represent an important characteristic in several genetic syndromes, in particular in 22q11.2DS 2 . It is estimated that 5% of the patients with cardiopathy have DGS, which is considered the second most common primary immunodeficiency [8] [9] [10] [11] .
Clinical manifestations that should arise suspicion for 22q11.2SD are CHD (75%), abnormal psychomotor development (68%), hypocalcemia-associated seizure (60%), velopharyngeal insufficiency with nasal voice (46%), genitourinary abnormalities (36%), skeletal abnormalities (17%) and facial dysmorphisms (11-17%) 2, [12] [13] [14] [15] . The immunological changes associated with 22q11.2DS are variable and secondary to thymic hypoplasia or agenesis, classically named DGS by immunologists 1, 5, [14] [15] [16] [17] .
The aim of this study is to describe the main cardiopathies, as well as phenotypic, metabolic and immunologic abnormalities in a series of 60 patients with 22q11.2DS.
Methods
This is a descriptive, transversal, retrospective and prospective study evaluating all patients with 22q11.2DS followed at the Allergy The molecular analysis of the microdeletion was conducted at the Cytogenomics Laboratory of the Department of Pathology, with fluorescent in situ hybridization (FISH) using a specific probe for the 22q11.2 region. Commercial probes of unique sequences were used for the specific region in 22q11.2 (probes DGS/VCFS, TUPLE1 and N25 D22S75, Cytocell, Cambridge, UK) 4, 19 and/or MLPA using various kits (P036-E1, P070-B2, P064-B3, MRC-Holland, Amsterdam, Netherlands -www.mlpa.com). Generated data were analyzed with the software GeneMarker® (Softgenetics, LLC, State College, PA, USA -www.softgenetics.com). These techniques are demonstrated in Figure 1 .
All patients underwent clinical and imaging evaluations at the Pediatric Cardiology Unit.
Immunocompetence was evaluated with complete blood count, measurement of serum immunoglobulin levels (IgG, IgM and IgA) by nephelometry, and determination of lymphocyte subpopulations in peripheral blood (flow cytometry -BD FACSCalibur) at the laboratory of the Central Institute of HC-FMUSP, using as comparison reference values already described 20, 21 .
Other performed tests included serum measurement of parathyroid hormone level (PTH, automated chemiluminescent enzyme immunoassay), ionic calcium, total calcium and phosphorus (automated colorimetric method), triiodothyronine (T3), thyroxine (T4), free thyroxine (free T4) and TSH (automated immunoassay), as well as determination of antithyroglobulin and antithyroperoxidase antibodies (indirect immunofluorescence). 
Results
The presence of CHDs was identified in 47 patients (77%) and surgical correction was performed in 34 of these, the most frequent of which were tetralogy of Fallot, ventricular septal defect and pulmonary artery atresy, as described in Table 1 and Graph 1.
Other important phenotypic features found in patients from the overall cohort with 22q11.2DS are shown in Table 2 . Facial features, as well as morphology of the ears, mouth, nose and eyes of some patients are shown in Figures 2 and 3.
The presence of facial dysmorphisms was not recognized during the neonatal period in many patients, becoming more evident with increasing age, as observed in Figure 4 .
Hypocalcemia was diagnosed in 27 of the 42 patients (64.2%) in whom ionic calcium was measured, 16 (59.3%) of which occurred in the neonatal period. Of these, PTH was measured in 27 patients and was found to be reduced in 7 patients (25.9%). Seizures occurred in 6 patients.
During follow-up of 20 patients with 22q11.2DS through school years and adolescence, we observed that 11 progressed with behavioral and psychiatric abnormalities. The most common finding was attention deficit hyperactivity disorder (ADHD) in 6 patients, 4 of which had the hyperactive/ impulsive type and 2 had the predominantly innatentive type. Other findings included learning disability (15%), anxiety (10%) and mental retardation (5%). Until present, none of the patients has progressed with compulsive-obsessive, schizoaffective or psychotic disorders.
In this study, low total lymphocyte count was found in 40% of the patients (18/45 cases), whereas low CD4 + lymphocytes occurred in 53.3% (16/30) and low CD8 + in 33.3% (10/30), as demonstrated in Graph 2. The evaluation of humoral immunity detected 2 patients with reduced IgM concentrations (29.6 mg/dL and 17.6 mg/dL) and one 9-month-old patient with IgG of 328 mg/dL, currently receiving replacement therapy with intravenous gamma globulin.
Discussion
Even though 22q11.2SD is considered in the literature to be a relatively frequent chromosomal abnormality, pediatricians, neonatologists and cardiologists in our country have not been recognizing it sistematically, and the publications with significant number of patients, particularly in the first year of life, are scarce 1, 2 . In a study conducted at Hospital das Clínicas of HC-FMUSP with 1,008 patients with primary immunodeficiency, only 32 patients with 22q11.2DS were 
27.7%
identified over 33 years 10 . These data led us to establish an active search of the microdeletion at the Pediatric Cardiology Unit of INCOR, resulting in a duplication of the number of cases over the past two years.
Cardiac malformations, observed in 77% of our cases, are the most critical manifestation of 22q11.2DS and affect between 49% and 95% of the patients according to the literature 1, 22 . A point to be highlighted in this cohort was the higher frequency of tetralogy of Fallot (38.3%) when compared with the literature in which frequencies between 17.6% and 20% have been described [22] [23] [24] . Another point to be emphasized in our study was the occurrence of ventricular septal defect associated with 22q11.2DS; this was the second most frequent CHD, which contrasts with the literature which shows that conotruncal heart defects are the most prevalent.
The recommendation for 22q11.2DS screening highlights that tests for the 22q11.2 chromosome microdeletion should be conducted in all newborns or children with tetralogy of Fallot, truncus arteriosus, interrupted aortic arch, isolated anomalies of the aortic arch and perimembranous ventricular septal defect with aortic arch anomaly. In all other patients with perimembranous ventricular septal defect without aortic arch anomaly or with any other type of CHD in association with characteristic phenotypic manifestations, clinical suspicion for 22q11.2DS should be raised and screening for the microdeletion should be conducted 3, 6, 22, 25 .
Another fact that draws attention for the importance of early diagnosis of 22q11.2DS, ideally before surgery for correction of the heart defect, is the observation that these patients present increased risk of post-operative complications, even though their mortality is comparable to that in patients with similar cardiopathies but without 22q11.2DS 26 .
In association with the CHDs mentioned above, the phenotypes found in this study, in particular the peculiar craniofacial dysmorphisms and the hypocalcemia in the neonatal period, are essential to raise diagnostic suspicion of 22q11.2DS. It should be mentioned that most of the clinical features of 22q11.2DS have been described in Caucasoid patients and for the first time, this study describes in details the facial dysmorphisms of the syndrome in the trihybrid Brazilian population, which since the XVI century has been formed by a mixture of Indians, Africans and Portugueses 27 .
Another interesting point addressed in this study and not yet presented in other descriptions was the evolving aspect of the facies and other dysmorphisms. Even though the dysmorphisms of 22q11.2DS recognized later in life (narrow palpebral fissures, elongated nose, overfolded ears) are already present at birth, the facies of the newborn and young infant draws less attention as a "syndromic facies" for the general pediatrician and/or cardiologist in this phase of life.
Palatal abnormalities occur in 9-16% of the patients with 22q11.2DS and are associated with a high morbidity. It is, therefore, fundamental to examine the palate carefully and include a search for bifid uvula which may suggest the presence of submucosal cleft palate 2, 14 . In this series, we observed that this finding was more frequent than that described in the literature. Goldmuntz et al in 2005 demonstrated that in addition to cleft palate, about 80% of the patients also present velopharyngeal insufficiency manifesting as nasal voice and compensatory articulation disorders 3 . Nasal voice is an underappreciated sign for suspicion of 22q11.2DS, probably because it is observed later in life, but it should be considered a warning sign for the occurrence of the syndrome.
Parathyroid hypoplasia or aplasia is very common in 22q11.2DS due to involvement of the third and fourth pharyngeal arches during embryogenesis. In 49% to 60% of the newborns affected by the syndrome, transient hypocalcemia may be present leading to tetany and seizures of difficult control 22 , data that was similar in the patients in this study. Pediatricians and cardiologists should be attentive during the neonatal period to the presence of hypocalcemia without other apparent physiopathological cause, a manifestation that is highly suggestive of the syndrome.
Another variable manifestation in 22q11.2DS is immunodeficiency, considered to be due to abnormal development of the thymus, denominated DGS in these cases. Around 80% of the patients with DGS have immune system abnormalities. Even though the thymus is hypoplasic or absent in great part of the patients, most present mild to moderate immunodeficiency, independent of other clinical features 28, 29 . A study conducted by Patel et al 29 showed that a minority of the patients have low immunoglobulin levels and, in general, between 2% and 3% need immunoglobulin replacement therapy 29 . In our study, 3 patients had low levels of immunoglobulins and only 1 patient required immunoglobulin replacement therapy.
Since in patients with 22q11.2DS the initial manifestation may be hyperactivity, anxiety and depression, the authors emphasize the importance of an early diagnosis and a multiprofessional follow-up appropriate for these patients. The diagnosis of ADHD, anxiety disorders, mood disorders and disorders of the autism spectrum can occur in one third to half of the children with the deletion. Mood abnormalities and psychotic disorders can increase significantly during early adulthood, it is therefore fundamental to monitor carefully the occurrence of psychiatric symptoms during adolescence and early adulthood 30 . These patients may also present poor academic performance, which is an important aspect to be addressed with the educational institutions.
It is imperative to disseminate warning signs for the 22q11.2DS among general pediatricians, neonatologists and pediatric cardiologists. Even though the pioneering proposal of Instituto da Criança and adopted by the Ministry of Health for detection of primary immunodeficiencies in the first year of life already includes 4 signs associated with the diagnosis of 22q11.2DS (CHD, in particular anomalies of the great vessels; lymphopenia < 2,500/mm; hypocalcemia with or without seizures; and absence of a thymic image on chest radiograph) 31, 32 it would be important to establish specific warning signs for this syndrome, adding phenotypic abnormalities and velopharyngeal insufficiency to the ones described above.
The current study has limitations peculiar to a transversal descriptive study, but highlights the main clinical and laboratorial findings of a highly selected population. The description of this population, however, allows us to identify and understand the demographic features of the studied group and the morbidity profile of the 22q11.2DS, and may offer data for a more adequate health policy for these patients.
The management of children with 22q11.2DS requires interaction of a multidisciplinary team of pediatrician, cardiologist, geneticist, and in some circumstances, endocrinologist, neurologist, plastic surgeon, psychologist and speech therapist.
Conclusion
Considering that in our country 2.5 million children are born each year, we estimate that 500 to 750 new cases of 22q11.2DS should be identified yearly, which indicates that the syndrome is currently underdiagnosed. It is therefore crucial to maintain an alert for the occurrence of the syndrome in the presence of CHD associated with hypocalcemia, facial dysmorphisms, velopharyngeal insufficiency, thymic hypoplasia or absence on chest radiograph, and confirm the diagnosis by identification of the microdeletion.
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